Immunocore Holdings plc
IMCR
$30.45
-$0.28-0.91%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 28.95% | 28.10% | 26.78% | 25.75% | 24.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.95% | 28.10% | 26.78% | 25.75% | 24.37% |
| Cost of Revenue | 9.27% | -121.62% | -97.13% | -59.69% | -725.76% |
| Gross Profit | 23.93% | 29.68% | 30.29% | 29.10% | 47.63% |
| SG&A Expenses | 6.18% | 6.58% | 3.88% | 3.62% | 7.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -9.29% | -2,112.37% | -2,112.37% | -2,112.37% | -2,112.37% |
| Total Operating Expenses | 17.38% | 11.33% | 8.16% | 7.55% | 16.98% |
| Operating Income | 51.11% | 60.75% | 61.94% | 59.17% | 13.44% |
| Income Before Tax | 63.92% | 47.68% | 62.22% | 65.40% | 13.06% |
| Income Tax Expenses | 987.24% | 116.36% | 52.25% | 79.31% | 66.98% |
| Earnings from Continuing Operations | 30.48% | 37.88% | 62.99% | 64.12% | 7.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.48% | 37.88% | 62.99% | 64.12% | 7.60% |
| EBIT | 51.11% | 60.75% | 61.94% | 59.17% | 13.44% |
| EBITDA | 53.62% | 63.84% | 65.16% | 62.62% | 14.61% |
| EPS Basic | 31.19% | 38.37% | 63.26% | 64.53% | 9.74% |
| Normalized Basic EPS | 50.40% | 45.11% | 59.78% | 63.37% | 21.13% |
| EPS Diluted | 31.47% | 38.68% | 62.84% | 64.15% | 9.37% |
| Normalized Diluted EPS | 50.67% | 45.39% | 59.25% | 62.89% | 20.71% |
| Average Basic Shares Outstanding | 0.65% | 0.69% | 0.95% | 1.49% | 2.26% |
| Average Diluted Shares Outstanding | 0.18% | 0.23% | 0.74% | 1.26% | 1.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |